Nanocopoeia is a privately held specialty research company based in St. Paul, MN, specializing in addressing high-value high-barrier, insolubility, bioavailability, and related drug product issues. Founded in 2001 through a technology license with the University of Minnesota, Nanocopoeia has restructured to focus on generating macro-particles for oral-solid drug development, demonstrating strong proof-of-concept in enhancing low solubility drug performance.
The company boasts a technically accomplished team and experienced industry management, led by Executive Chairman Mike Graves, who has over 20 years of industry experience in developing and commercializing pharmaceutical drug products. With a focus on patient safety, convenience, compliance, and effectiveness, Nanocopoeia aims to create valuable 505 b 2 opportunities through substantial investments and successful partnerships in the pharmaceutical industry.
Generated from the website